Literature DB >> 23075074

Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review.

Cheng-Bo Han1, Fan Li, Jie-Tao Ma, Hua-Wei Zou.   

Abstract

A meta-analysis was performed to compare KRAS gene mutations in colorectal cancer tissue samples with primary and metastatic colorectal cancers. A total of 19 publications with 986 paired primary and distant metastases and 171 paired primary and lymph node metastases showed that KRAS genotype was highly concordant in primary and distant metastatic tumors, indicating that either type of tumor tissue could be useful as a source to detect KRAS mutations for selection of anti-EGFR therapy. However, lymph-node-metastatic tumors might not be suitable for diagnostic analysis of KRAS mutations due to an obvious discordant rate between primary and lymph-node-metastatic tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23075074     DOI: 10.3109/07357907.2012.732159

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  32 in total

1.  Markers of resistance to anti-EGFR therapy in colorectal cancer.

Authors:  Walid Shaib; Reena Mahajan; Bassel El-Rayes
Journal:  J Gastrointest Oncol       Date:  2013-09

2.  Integrating anti-EGFR therapies in metastatic colorectal cancer.

Authors:  Sigurdis Haraldsdottir; Tanios Bekaii-Saab
Journal:  J Gastrointest Oncol       Date:  2013-09

Review 3.  Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie.

Authors:  Jonathan M Loree; Scott Kopetz; Kanwal P S Raghav
Journal:  J Gastrointest Oncol       Date:  2017-02

4.  The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.

Authors:  Shuang-Mei Zou; Wei-Hua Li; Wen-Miao Wang; Wen-Bin Li; Su-Sheng Shi; Jian-Ming Ying; Ning Lyu
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-31       Impact factor: 4.553

5.  Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer.

Authors:  F Graziano; A Ruzzo; E Giacomini; T Ricciardi; G Aprile; F Loupakis; P Lorenzini; E Ongaro; F Zoratto; V Catalano; D Sarti; E Rulli; C Cremolini; M De Nictolis; G De Maglio; A Falcone; G Fiorentini; M Magnani
Journal:  Pharmacogenomics J       Date:  2016-03-01       Impact factor: 3.550

6.  Addition of RAS Mutation Status May Strengthen the Predictive Model for Progression of Indeterminate Pulmonary Nodules.

Authors:  Yoshihiro Mise; Jean-Nicolas Vauthey; Scott Kopetz
Journal:  Ann Surg       Date:  2016-08       Impact factor: 12.969

Review 7.  Tumour heterogeneity: principles and practical consequences.

Authors:  Giorgio Stanta; Stephan Wenzel Jahn; Serena Bonin; Gerald Hoefler
Journal:  Virchows Arch       Date:  2016-07-13       Impact factor: 4.064

8.  Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.

Authors:  Britta Kleist; Marcel Kempa; Michael Novy; Christian Oberkanins; Li Xu; Guojun Li; Christiane Loland; Micaela Poetsch
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

9.  EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.

Authors:  Bryson W Katona; Yuanyuan Liu; Anqi Ma; Jian Jin; Xianxin Hua
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

10.  Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.

Authors:  Laurent Dercle; Lin Lu; Lawrence H Schwartz; Min Qian; Sabine Tejpar; Peter Eggleton; Binsheng Zhao; Hubert Piessevaux
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.